Novel inhibitory antibodies under Phase II/III/IV clinical trials have been identified as potential novel therapeutics for asthma using https://clinicaltrials.gov, for 5 of the highlighted genes [GATA3, IL1RL1, IL33, SMAD3, and TSLP (Table 7)]. This evidence concerns the gene IL1RL1 and asthma.